title: Dysregulation of Acetylation Enzymes Inanimal Models of Psychostimulant use Disorders: Evolving Stories.
abstract: Substance use disorders are neuropsychiatric illnesses that have substantial negative biopsychosocial impact. These diseases are defined as compulsive abuse of licit or illicit substances despite adverse medicolegal consequences. Although much research has been conducted to elucidate the pathobiological bases of these disorders, much remains to be done to develop an overarching neurobiological understanding that might be translatable to beneficial pharmacological therapies. Recent advances in epigenetics promise to lead to such an elucidation. Here I provide a brief overview of observations obtained using some models of psychostimulant administration in rodents. The review identifies CREB binding protein (CBP), HDAC1, HDAC2, HADC3, HDAC4, and HDAC5 as important players in the acetylation and deacetylation processes that occur after contingent or non-contingent administration of psychostimulants. These observations are discussed within a framework that suggests a need for better animal models of addiction in order to bring these epigenetic advances to bear on the pharmacological treatment of human addicts.
authors.affiliation: Molecular Neuropsychiatry Research Branch, NIDA Intramural Research Program, 251 Bayview Boulevard, Baltimore, MD 21224. JCADET@intra.nida.nih.gov.
authors.forename: Jean
authors.initials: J
authors.lastname: Lud Cadet
mesh_terms: D000107:Acetylation; D000818:Animals; D050882:CREB-Binding Protein / Q000378:metabolism; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D004195:Disease Models, Animal; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D019966:Substance-Related Disorders / Q000378:metabolism* / Q000473:pathology
chemical_list: D000697:Central Nervous System Stimulants; D050882:CREB-Binding Protein; D006655:Histone Deacetylases
references.citation: Neuron. 2012 Jan 12;73(1):108-20
references.pmid: 22243750
references.citation: Drug Alcohol Rev. 2014 Jan;33(1):4-12
references.pmid: 24251757
references.citation: Synapse. 2012 Jan;66(1):61-70
references.pmid: 21954104
references.citation: Neurol Sci. 2014 Feb;35(2):319-21
references.pmid: 24052450
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19186-91
references.pmid: 16380431
references.citation: Psychopharmacology (Berl). 2012 Feb;219(3):699-713
references.pmid: 21766169
references.citation: J Neurosci. 2013 Oct 9;33(41):16088-98
references.pmid: 24107942
references.citation: Int J Neuropsychopharmacol. 2013 Aug;16(7):1587-97
references.pmid: 23375146
references.citation: Nat Genet. 2008 Jul;40(7):897-903
references.pmid: 18552846
references.citation: Eur J Emerg Med. 2011 Aug;18(4):208-14
references.pmid: 21285880
references.citation: J Biol Chem. 2002 Jul 12;277(28):25748-55
references.pmid: 11948178
references.citation: Neurobiol Dis. 2013 Oct;58:132-43
references.pmid: 23726845
references.citation: Oncogene. 2007 Aug 13;26(37):5310-8
references.pmid: 17694074
references.citation: Biochem Cell Biol. 2001;79(3):253-66
references.pmid: 11467739
references.citation: Nature. 1993 Oct 28;365(6449):855-9
references.pmid: 8413673
references.citation: Acta Neuropathol. 2014 Jan;127(1):91-107
references.pmid: 24292887
references.citation: Cell. 2007 Nov 16;131(4):633-6
references.pmid: 18022353
references.citation: J Neurosci. 2011 Nov 23;31(47):16941-8
references.pmid: 22114264
references.citation: J Cardiovasc Magn Reson. 2014;16:26
references.pmid: 24758161
references.citation: Curr Pharm Des. 2013;19(28):5051-64
references.pmid: 23448461
references.citation: Cell. 2006 May 5;125(3):497-508
references.pmid: 16678094
references.citation: Int J Biochem Cell Biol. 2009 Jan;41(1):185-98
references.pmid: 18804549
references.citation: J Biol Chem. 1998 May 15;273(20):12599-605
references.pmid: 9575221
references.citation: Drug Alcohol Depend. 2012 Jan 1;120(1-3):35-40
references.pmid: 21794992
references.citation: Cell. 2009 Sep 4;138(5):1019-31
references.pmid: 19698979
references.citation: Cell Mol Life Sci. 2012 Jul;69(13):2173-87
references.pmid: 22286122
references.citation: PLoS One. 2013;8(3):e58473
references.pmid: 23469282
references.citation: Neuropsychopharmacology. 2010 Mar;35(4):913-28
references.pmid: 20010550
references.citation: Neurosci Lett. 2008 Feb 13;432(1):54-7
references.pmid: 18164815
references.citation: Neuroscience. 2008 Dec 2;157(3):644-55
references.pmid: 18848971
references.citation: J Biomed Biotechnol. 2011;2011:129383
references.pmid: 21049000
references.citation: Cell Mol Life Sci. 2010 Apr;67(8):1255-64
references.pmid: 20082207
references.citation: Front Pharmacol. 2014 Sep 02;5:204
references.pmid: 25228881
references.citation: Int J Biochem Cell Biol. 2009 Apr;41(4):736-9
references.pmid: 18725319
references.citation: BMC Genomics. 2013;14:545
references.pmid: 23937714
references.citation: Neuron. 2005 Oct 20;48(2):303-14
references.pmid: 16242410
references.citation: Brain Behav. 2012 Nov;2(6):732-40
references.pmid: 23170236
references.citation: BMC Genomics. 2013;14:606
references.pmid: 24010892
references.citation: Glia. 2009 Jan 1;57(1):1-12
references.pmid: 18627006
references.citation: Subcell Biochem. 2007;41:351-69
references.pmid: 17484136
references.citation: Ann N Y Acad Sci. 2003 Mar;983:84-100
references.pmid: 12724214
references.citation: Oncogene. 2007 Aug 13;26(37):5341-57
references.pmid: 17694077
references.citation: Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17335-40
references.pmid: 17956988
references.citation: Nat Neurosci. 2013 Apr;16(4):434-40
references.pmid: 23475113
references.citation: Mol Neurobiol. 2016 Jan;53(1):545-60
references.pmid: 25502297
references.citation: J Neurosci. 2013 Apr 10;33(15):6623-32
references.pmid: 23575859
references.citation: Science. 1968 Jan 19;159(3812):314-6
references.pmid: 5634500
references.citation: Adv Genet. 2010;70:101-41
references.pmid: 20920747
references.citation: Mol Neurobiol. 2015 Apr;51(2):696-717
references.pmid: 24939695
references.citation: Biol Psychiatry. 2014 Jul 1;76(1):47-56
references.pmid: 24239129
references.citation: Neuron. 2007 Nov 8;56(3):517-29
references.pmid: 17988634
references.citation: Clin Exp Metastasis. 2008;25(2):183-9
references.pmid: 18058245
references.citation: J Psychopharmacol. 2011 Feb;25(2):222-9
references.pmid: 19939859
references.citation: Nucleic Acids Symp Ser. 2000;(44):259-60
references.pmid: 12903367
references.citation: PLoS One. 2012;7(3):e34236
references.pmid: 22470541
references.citation: Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52
references.pmid: 23297220
references.citation: Behav Brain Res. 2007 Jul 19;181(1):76-84
references.pmid: 17477979
references.citation: Clin Psychopharmacol Neurosci. 2012 Dec;10(3):136-43
references.pmid: 23430970
references.citation: J Neurosci. 2008 Sep 17;28(38):9342-8
references.pmid: 18799668
references.citation: Am J Cardiovasc Drugs. 2009;9(3):177-96
references.pmid: 19463023
references.citation: FEBS J. 2015 May;282(9):1736-44
references.pmid: 25244360
references.citation: Neuron. 2009 May 14;62(3):335-48
references.pmid: 19447090
references.citation: Trends Endocrinol Metab. 2014 Jul;25(7):337-47
references.pmid: 24953190
references.citation: Lancet. 2013 Nov 9;382(9904):1564-74
references.pmid: 23993281
references.citation: Oncogene. 2007 Aug 13;26(37):5319-28
references.pmid: 17694075
references.citation: Neuropsychopharmacology. 2008 Nov;33(12):2981-92
references.pmid: 18288092
references.citation: Front Neurol. 2013 Nov 18;4:189
references.pmid: 24302917
references.citation: Curr Pharm Des. 2008;14(6):562-73
references.pmid: 18336301
references.citation: Nature. 1994 Jul 21;370(6486):223-6
references.pmid: 7913207
references.citation: Neuropsychopharmacology. 2008 Sep;33(10):2474-82
references.pmid: 18033234
references.citation: Oncogene. 2007 Aug 13;26(37):5450-67
references.pmid: 17694086
references.citation: Nat Rev Mol Cell Biol. 2014 Aug;15(8):536-50
references.pmid: 25053359